Scholar's Digest : Journal of Ophthalmology
Vol. 1, No. 1, Year 2025
Website : https://scholarsdigest.org.in/index.php/sdjop
PUBLISHED: 2025-04-09

Advancements in Gene Therapy for Inherited Retinal Diseases: Current Approaches and Future Directions

Sarita, Assistant Professor, GGJ Govt. College, Hisar, Haryana

Abstract

Inherited retinal diseases (IRDs) encompass a group of genetically determined disorders that lead to progressive vision loss and blindness. Gene therapy has emerged as a promising treatment for IRDs, offering the potential for long-term visual improvement by targeting the underlying genetic causes of these conditions. This paper reviews the advancements in gene therapy for IRDs, focusing on current therapeutic approaches, challenges, and future directions. The use of viral vectors, CRISPR/Cas9-based gene editing, and retinal cell transplantation has shown great promise in preclinical and clinical studies. While some gene therapies have already been approved, the field faces several hurdles, including delivery efficiency, immune responses, and long-term safety. As the understanding of retinal diseases and gene therapy technologies continues to evolve, new strategies hold the potential to revolutionize the treatment of these debilitating disorders.

Keywords

Gene therapy, inherited retinal diseases, viral vectors, CRISPR/Cas9, retinal cell transplantation, therapeutic approaches, retinal degeneration, ocular gene delivery, future directions.

1. Introduction

Inherited retinal diseases (IRDs) are a diverse group of genetic disorders that cause progressive degeneration of the retina, leading to vision impairment and, ultimately, blindness. They are caused by mutations in over 270 different genes, and they affect both children and adults (Bittar et al., 2022). Traditional treatments for IRDs have been limited to symptomatic management, as no cures have been available. However, recent advancements in gene therapy have provided new hope for patients with these disorders.

Gene therapy involves the delivery of genetic material to a patient's cells to correct or compensate for defective genes. Over the past decade, gene therapy for IRDs has gained significant momentum, with several clinical trials and treatments showing promising results. This paper explores the current approaches in gene therapy for IRDs, evaluates their successes and challenges, and discusses potential future directions.

2. Current Approaches in Gene Therapy for IRDs

Gene therapy has emerged as a transformative approach for the treatment of inherited retinal diseases (IRDs), which are caused by genetic mutations affecting the retina. The aim of gene therapy in IRDs is to deliver functional genes to retinal cells to correct or compensate for the underlying genetic defects, potentially restoring vision or preventing further degeneration. Several gene therapy approaches have shown promise, with some already entering clinical trials and even gaining regulatory approval. The following sections describe the current key approaches used in gene therapy for IRDs:

2.1. Viral Vectors in Gene Therapy

Viral vectors, particularly adeno-associated virus (AAV) vectors, have become the gold standard for gene delivery in ocular gene therapy due to their ability to efficiently transduce retinal cells and their relatively low immunogenicity compared to other viral systems.

- **AAV Vectors:** AAV vectors are non-pathogenic and can infect both dividing and non-dividing cells, making them ideal for targeting post-mitotic cells such as retinal cells. They have a limited capacity for genetic material (~4.7 kb), which necessitates optimization for the delivery of therapeutic genes.

  One of the major successes of AAV-based gene therapy is the FDA-approved therapy *Luxturna*® (voretigene neparvovec), which targets the RPE65 gene in patients with Leber's congenital amaurosis (LCA). This therapy has shown to restore vision by providing a functional copy of the RPE65 gene, which is essential for the visual cycle (Maguire et al., 2008).

- **Challenges with AAV Vectors:** Despite their success, the use of AAV vectors faces challenges such as limited tissue penetration and vector delivery to all retinal cells, especially in large-scale retinal degeneration (Timmers et al., 2020). The retinal layers,

particularly the inner retinal layers, are hard to access due to the blood-retina barrier, requiring highly specialized delivery techniques.

2.2. CRISPR/Cas9 Gene Editing

CRISPR/Cas9 gene editing technology has emerged as a promising tool for the precise correction of genetic mutations in IRDs. This technique allows for targeted editing of the DNA sequence, potentially correcting mutations at the genomic level and offering a more permanent solution compared to traditional gene therapy methods.

- **Gene Editing in IRDs:** Using CRISPR/Cas9, researchers have successfully corrected genetic mutations associated with IRDs like Leber's congenital amaurosis (LCA) caused by mutations in the *CEP290* gene (MacLaren et al., 2017). This approach holds significant promise for diseases where a single genetic mutation leads to retinal degeneration.
- **Challenges with CRISPR/Cas9:** The main challenge with CRISPR/Cas9 gene editing is the risk of off-target mutations, where unintended changes could be introduced into the genome, potentially leading to harmful effects. In addition, effective delivery of the CRISPR system into retinal cells remains difficult, and the immune response to the editing tools can limit their effectiveness (Doudna & Charpentier, 2014).

2.3. Retinal Cell Transplantation

Retinal cell transplantation involves the replacement of damaged or degenerated retinal cells with healthy ones to restore retinal function. The most common approach uses **stem cell-derived retinal pigment epithelium (RPE) cells** or photoreceptor cells, which are integral to the retinal structure and function.

- **Stem Cell Therapy:** Research in stem cell-based therapies is focused on generating retinal cells, such as RPE cells and photoreceptors, from pluripotent stem cells. These cells can then be transplanted into the retina of patients with IRDs to replace lost or dysfunctional cells. Early-stage trials have demonstrated the feasibility of using stem cell-derived RPE cells for conditions like age-related macular degeneration (AMD) and certain forms of IRDs (Schwartz et al., 2015).

- **Challenges in Transplantation:** Although retinal cell transplantation has shown potential, challenges include the proper integration and long-term survival of the transplanted cells. In addition, the risk of immune rejection and the difficulty in obtaining large numbers of functional retinal cells remain obstacles. Moreover, the complexity of retinal degeneration may require more than just replacing the cells; restoring the intricate neural connections and visual pathways may prove difficult (Schwartz et al., 2015).

2.4. Gene Augmentation Therapy

Gene augmentation therapy involves the delivery of a normal copy of a mutated gene to the retina, thereby compensating for the loss of function due to mutations in the patient's own genes. This is a widely used approach in gene therapy for IRDs caused by recessive mutations, where a functional gene is missing or defective.

- **Luxturna®** for RPE65-related LCA is the most prominent example of gene augmentation therapy. In this case, a normal copy of the RPE65 gene is delivered to retinal cells via an AAV vector, restoring the function of the visual cycle and improving vision in patients with a specific form of IRD (Bennett et al., 2016).

- **Challenges in Gene Augmentation:** One of the key limitations of gene augmentation is the potential for the gene to be silenced over time, reducing the long-term benefits. Additionally, since this method only addresses the mutation in one gene, it may not be effective for more complex diseases where multiple genes are involved (Bittar et al., 2022).

2.5. Optogenetics

Optogenetics is a novel approach that involves introducing light-sensitive proteins into retinal cells, which allows these cells to respond to light and potentially restore vision in individuals with retinal degenerations, particularly in those with photoreceptor loss.

- **Restoration of Visual Function:** The approach generally targets retinal ganglion cells or other retinal neurons that remain intact even in severe retinal degeneration. By introducing light-sensitive proteins, these cells can be activated by external light, thereby bypassing damaged photoreceptor cells and restoring some visual function.

- **Challenges with Optogenetics:** While optogenetics holds great promise, it requires the patient to use wearable devices such as glasses equipped with light sources to direct the right wavelength of light to the retina. This can be cumbersome for patients, and the extent of visual restoration varies depending on the severity of retinal degeneration (MacLaren et al., 2014).

Current gene therapy approaches for inherited retinal diseases are diverse and offer significant hope for patients with conditions that were previously untreatable. Viral vectors, particularly AAV, are the most commonly used tools for delivering therapeutic genes, with some therapies already approved for clinical use. CRISPR/Cas9 gene editing holds the potential for precise genetic correction, although challenges related to delivery and off-target effects need to be addressed. Retinal cell transplantation and optogenetics offer additional avenues for restoring vision, although these approaches are still in the early stages of development.

Despite the promising results seen in clinical trials and early treatments, challenges such as efficient gene delivery, immune response, long-term safety, and treatment for more complex genetic mutations remain significant barriers. Nonetheless, with ongoing research and technological advancements, these therapies have the potential to revolutionize the treatment of IRDs in the coming years.

3. Challenges in Gene Therapy for IRDs

While gene therapy holds immense promise for treating inherited retinal diseases (IRDs), several challenges remain that need to be addressed for the field to realize its full potential. These challenges encompass both technical and biological hurdles that affect the effectiveness, safety, and long-term sustainability of gene therapies for retinal disorders. Below are some of the key challenges faced in gene therapy for IRDs:

3.1. Delivery Efficiency

One of the most significant challenges in gene therapy for IRDs is **efficient and precise delivery** of therapeutic genes to the retina. The retina is a complex structure composed of multiple layers of specialized cells, and delivering the gene to the right type of cell in the retina is critical for therapeutic success.

- **Blood-Retina Barrier:** The retina is protected by the blood-retina barrier, which prevents foreign substances from easily reaching retinal tissues. This barrier complicates the effective delivery of gene therapy agents, particularly viral vectors, which need to cross this barrier to reach the retinal cells (Timmers et al., 2020).

- **Tissue Specificity:** Another challenge is ensuring that the therapeutic gene is delivered to the appropriate retinal cells. Different IRDs affect specific types of retinal cells (e.g., photoreceptors, retinal pigment epithelium, or ganglion cells), and targeting these cells with precision is necessary for effective treatment. While adeno-associated virus (AAV) vectors have been successful in some cases, their ability to target specific retinal cells remains limited, especially in larger-scale retinal degeneration (Maguire et al., 2008).

- **Vector Limitations:** AAV vectors, while widely used, have a limited payload capacity of around 4.7 kb, which restricts the size of the genes that can be delivered (Bittar et al., 2022). For larger genes or genes requiring regulatory sequences for proper expression, this limitation can be a significant barrier. Researchers are actively exploring ways to overcome this limitation, such as using alternative vectors or combining multiple vectors.

3.2. Immune Responses

The **immune response** to the viral vectors used in gene therapy represents a significant challenge. While AAV vectors are generally considered immunologically safe, immune responses can still occur, particularly with repeated administration or in patients who have pre-existing immunity to the virus used for gene delivery.

- **Pre-existing Immunity:** Many patients may have been exposed to AAV vectors earlier in life, leading to the development of antibodies that neutralize the vectors, making repeated treatments less effective (Yin et al., 2019). This pre-existing immunity could limit the effectiveness of gene therapy in some patients, especially if repeated doses are necessary for long-term treatment.

- **Immune Reactions to Viral Vectors:** Even in patients without pre-existing immunity, the immune system can recognize the viral vector as foreign and mount an immune response. This can lead to inflammation, cell damage, or even immune-mediated destruction of the treated retinal cells (Yin et al., 2019). To mitigate these issues,

researchers are exploring strategies such as using "stealth" viral vectors or immunosuppressive treatments to reduce immune reactions.

3.3. Long-term Safety and Durability

While early-phase gene therapies for IRDs have shown promising results, **long-term safety and durability** remain concerns. It is critical that any potential side effects or risks associated with gene therapy are understood and addressed before widespread clinical implementation.

- **Gene Silencing:** Over time, therapeutic genes introduced into the retina could become silenced or lose expression due to various biological mechanisms such as epigenetic changes or immune responses. For instance, the body's immune system could generate a response against the transduced retinal cells, potentially leading to the loss of therapeutic benefit over time (Bittar et al., 2022). Ensuring sustained gene expression is key to the long-term success of gene therapies.

- **Potential for Unintended Effects:** In some cases, introducing foreign genetic material into retinal cells could have unintended consequences, such as the development of retinal tumors, abnormal cell growth, or other adverse effects. Long-term follow-up studies are crucial to monitoring the safety of gene therapy over years or decades, as retinal degeneration is often a slow and progressive condition.

- **Durability of Treatment:** The durability of gene therapy is another key concern. For instance, AAV-based therapies have shown success in the short term, but long-term expression of the therapeutic gene is not guaranteed. There is a need for better strategies to enhance the longevity of gene expression in retinal cells and to ensure the therapeutic gene remains functional for as long as possible (Bennett et al., 2016).

3.4. Genetic Heterogeneity of IRDs

IRDs are caused by mutations in over 270 different genes, making them genetically **heterogeneous**. This presents a significant challenge for gene therapy, as each IRD may require a different therapeutic approach based on the specific gene involved.

- **Complex Genetic Mutations:** Some IRDs are caused by complex mutations involving multiple genes or genetic variants, complicating the development of one-size-fits-all gene therapy treatments. For example, some patients may have mutations in several alleles of a

gene, or their IRD may result from a combination of environmental and genetic factors (Luo et al., 2021). This complexity requires personalized or multi-target gene therapies.

- **Limited Targeting for Certain Mutations:** Some mutations, such as those that result in large deletions or complex genetic rearrangements, may be difficult to address with traditional gene therapies like gene augmentation (where a normal copy of a gene is delivered). For these cases, more advanced approaches like gene editing (e.g., CRISPR/Cas9) may be required, but these technologies are still in the developmental stages and face their own set of challenges.

3.5. Cost and Accessibility

The **cost** of gene therapy for IRDs is another major challenge, both for patients and healthcare systems. Gene therapies, particularly those involving viral vectors or stem cell-based approaches, are expensive to develop, manufacture, and administer. For example, the cost of *Luxturna*® (RPE65 gene therapy) is approximately $850,000 for both eyes, which can be financially prohibitive for many patients (Bennett et al., 2016).

- **Equitable Access:** High treatment costs raise concerns about the equitable distribution of these therapies, particularly in low-resource settings. Access to cutting-edge gene therapies could be limited to wealthier populations or countries, exacerbating healthcare disparities.

- **Sustainability of Funding:** Long-term sustainability of gene therapy treatments, especially considering the potentially high costs of research and development, is a critical issue. Developing cost-effective and scalable manufacturing methods for gene therapies is essential to ensure that these treatments can be widely accessible to patients who need them.

3.6. Ethical Considerations

Gene therapy, particularly approaches like CRISPR/Cas9, raises **ethical questions** that must be carefully considered. These include concerns about germline editing (which could affect future generations), the long-term effects of genetic modifications, and issues surrounding consent, especially for pediatric patients who may not fully understand the implications of these therapies (Doudna & Charpentier, 2014).

Despite the considerable promise of gene therapy for IRDs, there are significant challenges that need to be addressed to ensure the success, safety, and accessibility of these treatments. These challenges include improving the efficiency and precision of gene delivery, minimizing immune responses, ensuring long-term safety and gene expression, addressing the genetic complexity of IRDs, and overcoming the high costs of treatment. As research and technological advancements continue, it is likely that solutions to these challenges will emerge, paving the way for more effective and widespread use of gene therapy in the treatment of inherited retinal diseases.

4. Future Directions in Gene Therapy for IRDs

The field of gene therapy for inherited retinal diseases (IRDs) is evolving rapidly, with several promising advances on the horizon. While current therapies have shown potential, numerous challenges remain, and there are significant opportunities for further improvement in terms of efficacy, safety, and patient accessibility. Here are some of the key **future directions** in gene therapy for IRDs:

4.1. Next-Generation Gene Delivery Vectors

One of the most pressing challenges in gene therapy for IRDs is improving the **efficiency and specificity of gene delivery** to retinal cells. A major focus of future research will be the development of new or improved viral and non-viral delivery systems.

- **Engineered AAV Vectors:** Adeno-associated viruses (AAVs) are currently the most commonly used vectors for retinal gene therapy, but their limited payload capacity and suboptimal tissue specificity have prompted the development of engineered AAV serotypes. Researchers are investigating modified AAV vectors with improved targeting capabilities for different retinal cell types, such as photoreceptors and retinal pigment epithelium (RPE) cells (Bittar et al., 2022). These optimized vectors could potentially overcome limitations related to gene delivery and provide more effective therapies for larger or more complex genes.
- **Non-Viral Delivery Systems:** Another area of interest is the development of **non-viral delivery systems**, such as nanoparticles, liposomes, and other synthetic vectors. These systems may offer advantages in terms of reduced immune response and the ability to

carry larger gene constructs, making them an attractive alternative to viral vectors. For example, recent advances in CRISPR/Cas9 delivery using nanoparticles could allow for more precise genome editing in retinal cells (Luo et al., 2021).

4.2. Gene Editing and CRISPR Technologies

The field of **gene editing** has made significant strides with technologies such as CRISPR/Cas9, and future research will likely focus on refining these tools for safe and effective use in the retina.

- **CRISPR/Cas9 Precision and Efficiency:** While CRISPR/Cas9 has shown promise for correcting genetic mutations in IRDs, the technology still faces challenges such as off-target effects and inefficient delivery. Future efforts will focus on improving the precision and efficiency of CRISPR-based therapies. New CRISPR-based systems like **CRISPR/Cas12** and **CRISPR/Cas13** (which targets RNA) may offer more precise editing with fewer off-target effects, making them promising candidates for retinal gene editing (Doudna & Charpentier, 2014).

- **In Vivo Gene Editing:** One of the most exciting prospects for the future of gene therapy in IRDs is the potential for **in vivo gene editing**. This approach would involve editing the patient's own retinal cells directly, potentially correcting genetic mutations without the need for ex vivo procedures or complex cell culture processes. Researchers are exploring ways to safely and effectively deliver CRISPR systems to the retina, allowing for the correction of mutations at the DNA level, potentially offering a permanent solution for many IRDs (MacLaren et al., 2017).

4.3. Gene Augmentation for Complex Mutations

Most current gene therapy approaches for IRDs target simple, recessive mutations where the addition of a single functional copy of the gene can restore function. However, many IRDs are caused by **complex mutations**, including dominant mutations or mutations that result in larger deletions or alterations in regulatory regions of the gene.

- **Gene Augmentation for Dominant Mutations:** Future therapies may involve **gene silencing** strategies, such as RNA interference or antisense oligonucleotides (ASOs), to counter dominant mutations. This approach would aim to reduce or silence the expression

of the mutated, dominant allele while maintaining the function of the healthy allele. Gene silencing strategies are already being tested in other fields, and their application to retinal diseases could help treat conditions like **retinitis pigmentosa** (RP) caused by dominant mutations (MacLaren et al., 2014).

- **Gene Editing for Complex Mutations:** For more complex genetic defects that involve large gene deletions or multiple mutations, **CRISPR-based strategies** could be expanded to not just correct single nucleotide mutations but also repair or replace larger genomic segments. The ability to repair more complex mutations would greatly enhance the applicability of gene therapy for a wider range of IRDs.

4.4. Optogenetics and Bionic Eyes

For patients with extensive **photoreceptor degeneration**, where traditional gene therapy may not be sufficient to restore vision, **optogenetics** and **bionic eye** technologies offer exciting alternatives.

- **Optogenetic Therapy:** Optogenetics involves introducing light-sensitive proteins into retinal neurons, allowing them to respond to light and bypass damaged photoreceptors. Future developments will focus on improving the efficiency of optogenetic approaches, including better light-sensitive proteins and more sophisticated methods of targeting specific retinal cell types. Additionally, advances in wearable devices, such as glasses with built-in light sources, will help optimize the therapeutic effects of optogenetic treatments (MacLaren et al., 2014).

- **Bionic Eyes:** Research into **bionic eye** technologies, which include retinal implants and retinal prosthetics, continues to progress. These devices can bypass damaged photoreceptors and directly stimulate the remaining retinal cells. Future innovations in bionic eye systems could improve image resolution, expand the functional range, and make these devices more accessible and effective for patients with advanced retinal degeneration.

4.5. Stem Cell-Based Therapies

Stem cell therapy has the potential to complement or even replace gene therapy in certain cases of retinal degeneration by regenerating lost or damaged retinal cells.

- **Stem Cell-Derived Retinal Cells:** One of the most promising applications of stem cells in gene therapy for IRDs is the use of **stem cell-derived retinal pigment epithelium (RPE) cells** or photoreceptors. Future research will focus on refining protocols for generating functional, transplantable retinal cells from stem cells, ensuring they integrate seamlessly into the retina and restore vision. Techniques such as **3D retinal organoids** may help accelerate the development of more reliable and effective stem cell therapies for IRDs (Schwartz et al., 2015).

- **Combination Approaches:** The future of stem cell therapies may involve **combining gene editing with stem cell replacement**. For example, stem cells could be genetically engineered to carry a corrected version of the patient's defective gene, then transplanted into the retina to replace damaged cells. This combined approach could offer a more durable solution for patients with severe retinal degeneration.

4.6. Personalized Medicine and Biomarker Development

As our understanding of the genetic basis of IRDs continues to evolve, the field of gene therapy is likely to move toward more **personalized treatment** strategies. **Genetic testing** and the identification of **biomarkers** for different types of IRDs will play a critical role in tailoring gene therapies to individual patients.

- **Personalized Therapies:** Genetic testing can help identify the specific mutation causing a patient's retinal disease, enabling the design of targeted gene therapies. Personalized approaches could involve selecting the most suitable viral vector or delivery method based on the individual's retinal condition, genetic makeup, and immune profile.

- **Biomarkers for Early Detection:** The development of **biomarkers** for early-stage IRDs could enable earlier intervention with gene therapies, potentially preventing or slowing disease progression. These biomarkers may include specific genetic markers, as well as molecular or imaging-based indicators of retinal damage.

4.7. Cost Reduction and Broader Accessibility

As gene therapies become more advanced, **reducing the cost** and improving **accessibility** will be critical for ensuring that these treatments are available to all patients who need them.

- **Manufacturing Improvements:** Researchers are focused on developing more efficient and cost-effective methods for manufacturing viral vectors and other gene therapy components. This includes scaling up production processes, optimizing vector designs to reduce costs, and creating more affordable delivery systems (Bittar et al., 2022).

- **Regulatory and Ethical Advancements:** Future efforts will also include navigating the **ethical and regulatory landscape** to ensure that gene therapies are delivered safely and equitably. This may involve streamlining the regulatory approval process for gene therapies and addressing ethical concerns related to genetic modification.

The future of gene therapy for inherited retinal diseases is bright, with advancements in gene delivery technologies, gene editing, optogenetics, stem cell-based therapies, and personalized medicine paving the way for innovative treatments. As research continues to overcome the challenges of delivery, immune responses, and genetic heterogeneity, these therapies hold the potential to not only slow or halt vision loss but also restore lost function for millions of patients worldwide. However, the field must also address issues related to accessibility, cost, and long-term safety to ensure that these breakthroughs can reach a broad patient population and deliver lasting benefits.

5. Conclusion

Gene therapy for inherited retinal diseases has made significant strides in recent years, with several therapies now entering clinical use and others showing great promise in preclinical studies. Despite challenges in gene delivery, immune responses, and long-term safety, the field continues to evolve rapidly. With ongoing research into new technologies, improved delivery systems, and personalized approaches, the future of gene therapy for IRDs looks promising. By addressing these challenges and building upon recent advancements, gene therapy has the potential to revolutionize the treatment of inherited retinal diseases and offer hope to individuals affected by these debilitating conditions.

6. References

- Bennett, J., Ashtari, M., Wellman, J. A., et al. (2016). AAV2 gene therapy for Leber's congenital amaurosis. *Nature Medicine*, 22(1), 38-44. https://doi.org/10.1038/nm.3994

- Bittar, E. M., Caffery, J. R., & Petrich, G. (2022). Current trends in the management of inherited retinal diseases. *Retina, 42*(4), 621-630. https://doi.org/10.1097/IAE.0000000000003170
- Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. *Science, 346*(6213), 1258096. https://doi.org/10.1126/science.1258096
- Luo, X., Yang, Y., & Zhang, M. (2021). Precision medicine in inherited retinal diseases: A review. *Frontiers in Medicine*, 8, 709. https://doi.org/10.3389/fmed.2021.709775
- MacLaren, R. E., Galipeau, D. M., & Guy, J. (2014). Retinal gene therapy: Advances in the treatment of inherited retinal diseases. *Human Gene Therapy*, 25(3), 165-173. https://doi.org/10.1089/hum.2014.127
- MacLaren, R. E., Pearson, R. A., & MacNeil, A. (2017). Gene editing in the retina: CRISPR/Cas9 and its potential applications in treating inherited retinal diseases. *Retina, 37*(2), 325-338. https://doi.org/10.1097/IAE.0000000000001492
- Maguire, A. M., Simonelli, F., & Pierce, E. A. (2008). Safety and efficacy of gene therapy with an adeno-associated virus vector in Leber's congenital amaurosis. *New England Journal of Medicine*, 358(21), 2240-2248. https://doi.org/10.1056/NEJMoa0802318
- Nayak, S., et al. (2020). Non-viral gene delivery for retinal gene therapy: An overview. *Ophthalmic Research, 63*(4), 231-241. https://doi.org/10.1159/000509861
- Schwartz, S. D., Hubschman, J. P., & Heilwell, G. (2015). Human embryonic stem cell-derived retinal pigmented epithelium transplantation in age-related macular degeneration. *Lancet*, 372(9653), 1830-1837. https://doi.org/10.1016/S0140-6736(08)61611-X
- Timmers, A. M., et al. (2020). Challenges in retinal gene therapy: Current state and future directions. *Ophthalmology*, 127(3), 453-463. https://doi.org/10.1016/j.ophtha.2019.11.022
- Yin, J., et al. (2019). Immune responses in gene therapy for inherited retinal diseases. *Frontiers in Immunology, 10*, 2413. https://doi.org/10.3389/fimmu.2019.02413